Hemodynamic profile of SKP-450, a new potassium-channel activator

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 1, 1998, Pages 85-94

  Lee, Byung Ho ^a   Yoo, Sung Eun ^a   Shin, Hwa Sup ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Antihypertension; Hemodynamics; KR 30450; Potassium channel activator; SKP 450

Indexed keywords

2 (1,3 DIOXOLAN 2 YL) 2 METHYL 6 NITRO 4 (2 OXO 1 PYRROLIDINYL) 2H 1 BENZOPYRAN; 2 (2'' (1'',3'' DIOXOLAN 2 YL) 2 METHYL 4 (2' OXOPYRROLIDIN 1 YL) 6 NITRO 2H 1 BENZOPYRAN; ADENOSINE TRIPHOSPHATE; BENZOPYRAN DERIVATIVE; DEOXYCORTICOSTERONE ACETATE; GLIBENCLAMIDE; LEMAKALIM; N,N DIMETHYLFORMAMIDE; POTASSIUM CHANNEL STIMULATING AGENT; PROPRANOLOL; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOG; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENCY; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEMODYNAMICS; HYPERTENSION; INTRADUODENAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; SPONTANEOUSLY HYPERTENSIVE RAT; SUBCUTANEOUS DRUG ADMINISTRATION; VASCULAR RESISTANCE;

ANESTHESIA; ANIMALS; BENZOPYRANS; BLOOD PRESSURE; CORONARY CIRCULATION; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; HEMODYNAMIC PROCESSES; HYPERTENSION; MALE; POTASSIUM CHANNELS; PYRROLIDINONES; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY;

EID: 0013398623     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199801000-00013     Document Type: Article

References (33)

1. Cook NS. The pharmacology of potassium channels and their therapeutic potential. Trends Pharmacol Sci 1988;9:21-8.
2. Hamilton TC, Weston AH. Cromakalim, nicorandil and pinacidil: novel drugs which open potassium channels in smooth muscle. Gen Pharmacol 1989;20:1-9.
3. Howe BB, Halterman TJ, Yochim CL, et al. ZENECA ZD6169: a novel KATP channel opener with in vivo selectivity for urinary bladder. J Pharmacol Exp Ther 1995;274:884-90.
4. Hof RP, Umemura K, Evenou JP, Hof A, Ruegg PC. Effects of isradipine on plasma renin activity in sodium-loaded and -depleted conscious rabbits. J Cardiovasc Pharmacol 1992;19:503-7.
5. Weston AH, Longmore J, Newgreen DT, Edwards G, Bray KM, Duty S. The potassium channel openers: a new class of vasorelaxants. Blood Vessels 1990;27:306-13.
6. Vidai MJ, Romero JC, Vanhoutte PM. Endothelium-derived relaxing factor inhibits renin release. Eur J Pharmacol 1988;149:401-2.
7. Buckingham RE. Studies on the anti-vasoconstrictor activity of BRL 34915 in spontaneously hypertensive rats: a comparison with nifedipine. Br J Pharmacol 1988;93:541-52.
8. Sigmon DH, Beierwaltes WH. Endothelium-derived constricting factor in renovascular hypertension. Hypertension 1995;25:803-8.
9. + channel-opening properties of a novel compound, NIP-121, in guinea pig myocardium as compared with those of cromakalim. J Cardiovasc Pharmacol 1995;26:608-13.
10. Damiano BO, Giardino EC, Haertlein BJ, Stump GL, Mitchell JA, Falotico R. Cardiovascular profile of RWJ 29009, a new potassium channel activator, in anesthetized and conscious dogs. J Cardiovasc Pharmacol 1994;23:300-10.
11. Uchida W, Masuda N, Taguchi T, et al. Pharmacologic profile of YM934, a novel potassium channel opener. J Cardiovasc Pharmacol 1994;23:180-7.
12. Izumi H, Jinno Y, Kaneta S. et al. Effects of KRN4884, a novel K channel opener, on the cardiovascular system in anesthetized dogs: a comparison with levcromakalim, nilvadipine, and nifedipine. J Cardiovasc Pharmacol 1995;26:189-97.
13. Grover GJ, McCullough JR, D'Alonzo AJ, Sargent CA, Atwal KS. Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448. J Cardiovasc Pharmacol 1995;25:40-50.
14. Grover GJ, Dzwonczyk S, Parham CS, Sleph PG. The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs. Cardiovasc Drugs Ther 1990;4:465-74.
15. + channels protect the myocardium against ischemia/reperfusion damage. Circ Res 1991;69:571-81.
16. Tanaka H, Okazaki K, Shigenobu K. Cardioprotective effects of NIP-121, a novel ATP-sensitive potassium channel opener, during ischemia and reperfusion in coronary perfused guinea pig myocardium. J Cardiovasc Pharmacol 1996;27:695-701.
17. Weston AH, Edward G. Recent progress in potassium channel opener pharmacology. Biochem Pharmacol 1992;43:47-54.
18. Longman SD, Hamilton TC. Potassium channel activator drugs -mechanism of action, pharmacological properties, and therapeutic potential. Med Res Rev 1992;12:73-148.
19. + channel. J Pharmacol Exp Ther 1995;275:807-12.
20. + channel: a comparison with pinacidil and lemakalim. Circ Res 1991;69:1152-8.
21. Cangiano JL, Rodriguez-Sargent C, Martinez-Maldonado M. Effects of antihypertensive treatment on systolic blood pressure and renin in experimental hypertension in rats. J Pharmacol Exp Ther 1979;208:310-3.
22. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;252:726-32.
23. Tamargo J, Delpon PE, Garcia-Rafanell J, Gomez L, Cavalcanti F. Cardiovascular effects of the novel potassium channel opener UR-8225. J Cardiovasc Pharmacol 1995;26:295-305.
24. Falotico R, Keizser J, Haertlein B, Cheung W, Tobia A. Increased vasodilator responsiveness to BRL 34915 in spontaneously hypertensive versus normotensive rats: contrast with nifedipine. Proc Soc Exp Biol Med 1989;190:179-85.
25. Masuda Y, Arakawa C, Yokoyama T, Shigenobu K, Tanaka S. The antihypertensive property of NIP-121, a novel potassium channel opener in rats. J Cardiovasc Pharmacol 1991;18:190-7.
26. Paciorek PM, Burden DT, Burke YM, et al. Preclinical pharmacology of Ro 31-6930. a new potassium channel opener. J Cardiovasc Pharmacol 1990;15:188-97.
27. Gibbs CL, Cardiac energetics. Physiol Rev 1978;58:174-248.
28. Smallwood JK, Steinberg MI. Cardiac electrophysiological effects of pinacidil and related pyridylcyanoguanidines: relationship to antihypertensive activity. J Cardiovasc Pharmacol 1988; 12:102-9.
29. + channel activity and contractile behavior in mammalian ventricle by the potassium channel openers cromakalim and RP49356. J Pharmacol Exp Ther 1990;255:429-35.
30. Edwards G, Weston AH. The pharmacology of ATP-sensitive potassium channels. Annu Rev Pharmacol Toxicol 1993;33:597-637.
31. + channel openers, a class of drugs with vasorelaxant and cardioprotective properties. Life Sci 1990;47:1693-705.
32. + channel openers and "natural" cardioprotection. Trends Pharmacol Sci 1990;13:269-72.
33. Longman SD, Clapham JC, Wilson C, Hamilton TC, Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil. J Cardiovasc Pharmacol 1988;12:535-42.